ES2186686T3 - Metodo de inmunomodulacion por medio de transferencia adoptiva de linfocitos t-citotoxicos especificos de antigenos. - Google Patents

Metodo de inmunomodulacion por medio de transferencia adoptiva de linfocitos t-citotoxicos especificos de antigenos.

Info

Publication number
ES2186686T3
ES2186686T3 ES94917635T ES94917635T ES2186686T3 ES 2186686 T3 ES2186686 T3 ES 2186686T3 ES 94917635 T ES94917635 T ES 94917635T ES 94917635 T ES94917635 T ES 94917635T ES 2186686 T3 ES2186686 T3 ES 2186686T3
Authority
ES
Spain
Prior art keywords
cytotoxy
lymphocytes
antigen
specific antigen
adoptive transfer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94917635T
Other languages
English (en)
Inventor
Claudio Bordignon
Fulvio Mavilio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Application granted granted Critical
Publication of ES2186686T3 publication Critical patent/ES2186686T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

UN METODO PARA LA PRODUCCION DE CELULAS T CITOTOXICAS (CTLS) ESPECIFICAS DE ANTIGENOS MEDIANTE LA INCUBACION DE UNA PREPARACION QUE CONTENGA CELULAS T CON DICHO ANTIGENO Y AISLAR DICHAS CTLS ESPECIFICAS DE ANTIGENOS, QUE SE CARACTERIZA PORQUE I) SE ACTIVA LA PROLIFERACION DE CTLS EN LA PREPARACION CELULAR MEDIANTE UNA INCUBACION CON EL ANTIGENO; II) SE TRANSFIERE SELECTIVAMENTE UN VECTOR A LAS CTLS PROLIFERANTES, EN DONDE DICHO VECTOR CONTIENE UN GEN MARCADOR CON EL QUE SE PUEDEN SEPARAR LAS CELULAS MARCADAS Y LAS NO MARCADAS; E III) SE SEPARAN LAS CTLS ESPECIFICAS DE ANTIGENOS TRANSFECTADAS EN BASE A DICHO GEN MARCADOR, QUE ES UTIL PARA UNA INMUNOMODULACION.
ES94917635T 1994-05-16 1994-05-16 Metodo de inmunomodulacion por medio de transferencia adoptiva de linfocitos t-citotoxicos especificos de antigenos. Expired - Lifetime ES2186686T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1994/001573 WO1995031208A1 (en) 1994-05-16 1994-05-16 Method of immunomodulation by means of adoptive transfer of antigen-specific cytotoxic t-cells

Publications (1)

Publication Number Publication Date
ES2186686T3 true ES2186686T3 (es) 2003-05-16

Family

ID=8165855

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94917635T Expired - Lifetime ES2186686T3 (es) 1994-05-16 1994-05-16 Metodo de inmunomodulacion por medio de transferencia adoptiva de linfocitos t-citotoxicos especificos de antigenos.

Country Status (11)

Country Link
EP (1) EP0804210B1 (es)
JP (1) JP3288708B2 (es)
KR (1) KR100219258B1 (es)
AT (1) ATE228368T1 (es)
AU (1) AU691501B2 (es)
DE (1) DE69431808T2 (es)
DK (1) DK0804210T3 (es)
ES (1) ES2186686T3 (es)
NO (1) NO319331B1 (es)
PT (1) PT804210E (es)
WO (1) WO1995031208A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063375A (en) * 1996-09-10 2000-05-16 Medical University Of South Carolina Semiallogeneic cell hybrids and related methods for treating cancer
GB0224442D0 (en) 2002-10-21 2002-11-27 Molmed Spa A delivery system
KR100882445B1 (ko) 2007-03-16 2009-02-09 울산대학교 산학협력단 항―４－１ｂｂ 항체를 이용한 항원 특이적 자가유래ｃｄ８＋ｔ 세포의 분리 및 증식 방법
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
WO2013119947A1 (en) 2012-02-09 2013-08-15 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
JP6999941B2 (ja) 2015-09-18 2022-02-10 ベイラー カレッジ オブ メディスン 病原体からの免疫原性抗原同定および臨床的有効性との相関

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06501161A (ja) * 1990-09-14 1994-02-10 ザ　ジョーンズ　ホプキンス　ユニバーシティー 抗腫瘍免疫性の強化と遺伝子治療のための組成物及び方法
US5529774A (en) * 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells

Also Published As

Publication number Publication date
NO319331B1 (no) 2005-07-18
EP0804210A1 (en) 1997-11-05
ATE228368T1 (de) 2002-12-15
JP3288708B2 (ja) 2002-06-04
NO964896D0 (no) 1996-11-18
DE69431808D1 (de) 2003-01-09
KR100219258B1 (ko) 1999-09-01
WO1995031208A1 (en) 1995-11-23
JPH09507643A (ja) 1997-08-05
DE69431808T2 (de) 2003-09-18
EP0804210B1 (en) 2002-11-27
AU6928194A (en) 1995-12-05
AU691501B2 (en) 1998-05-21
DK0804210T3 (da) 2003-03-10
PT804210E (pt) 2003-04-30
NO964896L (no) 1996-11-18

Similar Documents

Publication Publication Date Title
Modlński The role of the zona pellucida in the development of mouse eggs in vivo
Gazdar et al. Characterization of paired tumor and non‐tumor cell lines established from patients with breast cancer
BR0012099A (pt) Transferência citoplásmica para de-diferenciar células recipientes
ES2179666T3 (es) Transferencia de materiales al interior de celulas empleando silicio poroso o policristalino.
DK639689D0 (da) Indfoering af dna i celler
ES2177706T3 (es) Componentes de utilidad en celulas electroquimicas y su uso en la separacion de oxigeno.
CY1111098T1 (el) Bodipy διαιθυλοακεταλη αμινοακεταλδεϋδης
BR9710968A (pt) Antìgenos de célula b humana; reagentes correlatos
DE69940265D1 (de) Alzheimersche krankheit sekretase
PA8429201A1 (es) Virosomas cationicos como sistema de transferencia para material genetico
ES2186686T3 (es) Metodo de inmunomodulacion por medio de transferencia adoptiva de linfocitos t-citotoxicos especificos de antigenos.
BR9811675A (pt) Genes isolados para proteìna da membrana de célula dentrìtica
EP0317810A3 (de) Verfahren und Vorrichtung zum Ablösen von Zellkulturen von Mikroträgern
Teramoto et al. The structure of the mouse mammary tumor virus: isolation and characterization of the core
AU2088997A (en) Method of identifying mhc-class i restriced antigens endogenously processed by a cellular secretory pathway
ES2053967T3 (es) Identificacion de celulas nk y linfocitos t citotoxicos.
ES2107451T3 (es) Proceso de fermentacion para la produccion de desoxirribonucleosidos de pirimidina.
NO904791D0 (no) Fremgangsmaate for biokjemisk oksydasjon av steroider samtgenetisk omvandlede celler for anvendelse deri.
CO4650227A1 (es) Metodo para inmortalizar celulas
EP0061253A3 (en) Process for the transfer of genetic material into actinomycete cells, prepared cells and method of culturing these cells and isolating a metabolite
ATE180893T1 (de) Chromatographiematerial
DK1048725T3 (da) Fremgangsmåde til fremstilling af pattedyrcellelinjer
Kimura Further evidence of the similarity of microtubule protein from mitotic apparatus and sperm tail of the sea urchin, as a substrate in thiol-disulfide exchange reaction
DE3750009D1 (de) Polyakrylsäure-klebemittel und zelltrennanordnung.
CO4790179A1 (es) Procedimiento para la fabricacion de proteinas humanas por activacion genica endogena